Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
15 mars 2023 11h55 HE
|
Trethera Corporation
LOS ANGELES, March 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
24 janv. 2023 12h12 HE
|
Trethera Corporation
LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
JAPAN HOUSE Los Angeles Presents “Designing With Disaster: Stories From Seven Regenerative Cities”
05 janv. 2023 09h00 HE
|
JAPAN HOUSE Los Angeles
LOS ANGELES, Jan. 05, 2023 (GLOBE NEWSWIRE) -- JAPAN HOUSE Los Angeles, a Japanese cultural destination in the heart of Hollywood, announces its upcoming exhibition “Designing with Disaster: Stories...
NewHydrogen reports progress in its quest to lower the cost of producing green hydrogen
20 déc. 2022 03h30 HE
|
NewHydrogen, Inc.
NewHydrogen CEO highlights the company’s milestones, and outlines next steps SANTA CLARITA, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC: NEWH), a developer of a breakthrough...
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
08 nov. 2022 10h00 HE
|
NeuroSigma, Inc.
Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...
Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program
19 oct. 2022 12h17 HE
|
Trethera Corporation
LOS ANGELES, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting
04 oct. 2022 12h23 HE
|
Trethera Corporation
LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Sprouts Farmers Market Aligns with Arizona State University, University of California, Los Angeles, University of Southern California, and University of Texas to Empower Women’s Sports and Health
13 sept. 2022 12h00 HE
|
SFM, LLC d/b/a Sprouts Farmers Market
PHOENIX, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sprouts Farmers Market today announced a complement to its long-term commitment and investment to women’s athletics through individual sponsorship...
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
07 sept. 2022 12h37 HE
|
Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Revolutionary Aneutronic Fusion Energy Generator Being Built By Kronos Fusion Energy With Carl Weggel Leading Its Design
17 août 2022 08h00 HE
|
Kronos Fusion Energy
ARLINGTON, Va., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Carl Weggel—a 50-year persistent advocate of the compact, ultra-high-field tokamak—is on a mission to commercialize fusion energy through Kronos's...